Apple's (AAPL) initial foldable iPhone production is limited to just a few hundred units per day as the company and its suppliers work to ramp up output while meeting quality standards, Nikkei sources report
Newsquawk Staff ·
Apple's (AAPL) initial foldable iPhone production is limited to just a few hundred units per day as the company and its suppliers work to ramp up output while meeting quality standards, Nikkei sources report.
What it means
Early production reports of this kind are standard for a first-generation form factor: new Apple product categories have historically started at constrained daily output while yield and quality gates are worked through, with initial unit rates bearing little relation to launch-quarter volumes. The transmission channel here runs through the supply chain rather than the handset line itself: foldable-specific components such as hinge assemblies and flexible display panels carry the bottleneck, and the read-across is to the named panel and hinge suppliers and to any existing foldable peer set in Android, where a slow Apple ramp delays category legitimisation rather than confirming it. The distinction worth drawing is between a yield problem and a deliberate low-volume pilot phase; limited daily output this far from any announced launch fits the latter pattern and has tended to resolve upward as ramp schedules are confirmed. What follows in past episodes of this kind is a sequence of supplier order disclosures, capacity additions, and eventual volume guidance, each of which has moved the chain more than the original production report. As a Nikkei sourcing piece rather than company confirmation, the signal is directional on timing, not on demand.
Sources
- Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand
- OpenAI trims valuation target to USD 1.25tln after previously pitching a higher price, according to FT
- OpenAI is raising up to USD 30bln in funding round at a USD 1.25tln valuation, led by UAE investors, according to CNBC, citing sources; OpenAI is negotiating a commercial deal that would secure more computing capacity from the UAE
- Western Digital (WDC) Q1 2027 (USD): Adj. EPS 4.64 (exp. 4.08), Revenue 4.38bln (exp. 4.14bln)
- US EQUITY OPEN: Mag-7 earnings lead Tech and Indices lower as the Middle East situation remains fragile
Related headlines
- Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone9 hours ago
- Moderna (MRNA) downside attributed to early data leaks (link below) - UNCONFIRMED11 hours ago
- State of Rhode Island sues Meta (META) over alleged tolerance for scam advertising11 hours ago
- Nvidia (NVDA) launches Minerva platform for end-to-end AI factory observability13 hours ago
- Meta's (META) 5yr CDS hits an all-time high at 114.5bps14 hours ago
- Google (GOOGL) is launching an agent compute engine15 hours ago
- US PREMARKET MOVERS: META, TSLA, IBM, LRCX, BX, PG, CMCSA, SAP, BABA15 hours ago
- Newmont (NEM) says production growth is expected to begin in 2027 following previously flagged 2026 trough, adds Q3 gold production was broadly flat sequentially as anticipated6 hours ago
- Uber (UBER) puts all 30,000 employees on ChatGPT Work12 hours ago
- Newsquawk Daily US Earnings Estimates - 23rd October 2026: AXP12 hours ago
- Fireblocks denies talks with Visa (V), CoinDesk reports13 hours ago
- Norfolk Southern (NSC) says tightening truck capacity is improving rail competitiveness, supporting truck-to-rail conversions and stronger customer demand14 hours ago
- Procter & Gamble (PG) CFO says 'so far, consumer has held up, we don't know if that's going to continue'14 hours ago
- eBay (EBAY) confirms plans to reduce workforce by 9%; expects Q3 results above guidance 15 hours ago
- AbbVie (ABBV) announces positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa15 hours ago